Veracyte (VCYT)

Veracyte Stock Analysis & Ratings

VCYT Stock Chart & Stats

Day’s Range$17.11 - $18.67
52-Week Range$14.85 - $54.13
Previous Close$16.48
Average Volume (3M)928.62K
Market Cap$1.30B
P/E Ratio-26.4
Next EarningsAug 03, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score7
EPS (TTM)-0.69



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $14.85 and its highest was $54.13 in the past 12 months.
    What is Veracyte’s market cap?
    Veracyte’s market cap is $1.30B.
      What is Veracyte’s price target?
      The average price target for Veracyte is $37.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $60.00 ,the lowest forecast is $23.00. The average price target represents 103.74% Increase from the current price of $18.16.
        What do analysts say about Veracyte?
        Veracyte’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
          When is Veracyte’s upcoming earnings report date?
          Veracyte’s upcoming earnings report date is Aug 03, 2022 which is in 79 days.
            How were Veracyte’s earnings last quarter?
            Veracyte released its earnings results on May 03, 2022. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.032.
              Is Veracyte overvalued?
              According to Wall Street analysts Veracyte’s price is currently Undervalued.
                Does Veracyte pay dividends?
                Veracyte does not currently pay dividends.
                What is Veracyte’s EPS estimate?
                Veracyte’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Veracyte have?
                Veracyte has 71,450,000 shares outstanding.
                  What happened to Veracyte’s price movement after its last earnings report?
                  Veracyte reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went up 4.613%.
                    Which hedge fund is a major shareholder of Veracyte?
                    Among the largest hedge funds holding Veracyte’s share is ARK Investment Management LLC. It holds Veracyte’s shares valued at 241M.


                      Veracyte Stock Analysis

                      The Veracyte stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description


                      Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

                      Similar Stocks
                      Price & Change
                      Rosetta Genomics
                      Quest Diagnostics
                      Exact Sciences

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis